A Randomized, Open-Label, 2-Stage Study of INCB047986 Administered Orally to Subjects With Primary Myelodysplastic Syndrome (MDS) Refractory to or Unlikely to respond to ESAs.
The specific purpose of this study is to test the effects, good and bad, of INCB047986 (referred to as the study drug) in people with Myelodysplastic Syndrome (MDS) at different dose levels. Another purpose of the study is to test the effects, good and bad, of the study drug in combination with Erythropoiesis-stimulating agents (ESAs).
Myelodysplastic Syndrome (MDS) Refractory to or Unlikely to Respond to Erythropoiesis-Stimulating Agents (ESAs)
18+ years of age
MDS diagnosis according to WHO classification for de novo or primary MDS
no prior hypomethylating agents or immunosuppressive therapy for MDS
18 - 110
Healthy Volunteers Needed
Duration of Participation
At least 16 weeks - indefinite as long as participants are receiving benefit from study treatment
Nan Subbiah 503-494-4603
Clinical Trials Information Line: Phone 503-494-1080 or email@example.com